We find elevated tumour SLFN11 not only linked to improved clinical outcome to chemotherapy in SCLC but to an extent is also associated with olaparib sensitivity in platinum-sensitive HGSOC patients. The gene discussed is SLFN11; the disease is small cell lung carcinoma.